A RANDOMIZED, ACTIVE-CONTROLLED, DOUBLE-BLIND, MULTICENTER, PHASE 3 CLINICAL FOLFOX VERSUS BEVACIZUMAB IN COMBINATION WITH FOLFOX FOR THE FIRST-LINE STUDY OFLVONESCIMAB IN COMBINATION WITH TREATMENT OF METASTATIC COLORECTAL CANCER
- Registry ID
- SMT112-3005
- Source registry
- HEALTH_CANADA
- Status
- Ongoing
- Phase
- PHASE3
- Study type
- INTERVENTIONAL
- Sponsor
- SUMMIT THERAPEUTICS INC.
- Start date
- 2026-05-01
- Last update
- 2025-12-10
Conditions
- METASTATIC COLORECTAL CANCER
Related clinical trials
- A RANDOMIZED, DOUBLE BLIND, PHASE 3 STUDY OF STANDARD-OF-CARE CHEMOTHERAPY AND BEVACIZUMAB WITH OR WITHOUT INCA33890 IN THE FIRST LINE TREATMENT OF METASTATIC MICROSATELLITE STABLE COLORECTAL CANCER
- AN INTERVENTIONAL, PHASE 3, DOUBLE-BLIND, RANDOMIZED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF PF-08634404 IN COMBINATION WITH CHEMOTHERAPY VERSUS BEVACIZUMAB IN COMBINATION WITH CHEMOTHERAPY IN TREATMENT-NAÏVE PARTICIPANTS WITH METASTATIC COLORECTAL CANCER
- ROSETTA CRC-203: A BLINDED, RANDOMIZED PHASE 2/3 STUDY OF PUMITAMIG IN COMBINATION WITH CHEMOTHERAPY VERSUS BEVACIZUMAB IN COMBINATION WITH CHEMOTHERAPY IN PARTICIPANTS WITH PREVIOUSLY UNTREATED, UNRESECTABLE, OR METASTATIC COLORECTAL CANCER
- A PHASE 3, RANDOMIZED, OPEN-LABEL, MULTICENTER CLINICAL STUDY TO EVALUATE
THE SAFETY AND EFFICACY OF MK-1084, CETUXIMAB, AND MFOLFOX6 VERSUS
MFOLFOX6 WITH OR WITHOUT BEVACIZUMAB AS FIRST-LINE TREATMENT OF
PARTICIPANTS WITH KRAS G12C-MUTANT, LOCALLY ADVANCED UNRESECTABLE OR
METASTATIC COLORECTAL CANCER (KANDLELIT-012)
- A PHASE 2, OPEN-LABEL, RANDOMIZED, MASTER PROTOCOL STUDY TO EVALUATE SAFETY AND EFFICACY OF MULTIPLE TREATMENT COMBINATIONS WITH TELISOTUZUMAB ADIZUTECAN IN SUBJECTS WITH METASTATIC COLORECTAL CANCER
- A PHASE 1, FIRST-IN-HUMAN, DOSE-ESCALATION STUDY OF TORL-3-600 IN PARTICIPANTS
WITH ADVANCED CANCER
View on source registry